Drugs Containing Excipient (Inactive Ingredient) CINQUASIA RED

Generic drugs containing CINQUASIA RED excipient

Company	Ingredient	NDC	Excipient
Ingenus Pharmaceuticals LLC	scopolamine	50742-505	CINQUASIA RED

CINQUASIA RED: Market Dynamics and Financial Trajectory for a Pharmaceutical Excipient

Last updated: February 17, 2026

CINQUASIA RED is a pigment excipient used in pharmaceutical formulations, primarily for oral solid dosage forms, conferring a distinct red color. Its market performance is driven by demand from drug manufacturers for aesthetic appeal and product differentiation, alongside regulatory compliance and quality assurance. The financial trajectory of CINQUASIA RED is influenced by raw material costs, manufacturing efficiencies, global pharmaceutical production volumes, and the competitive landscape of excipient suppliers.

What is CINQUASIA RED and its Primary Applications?

CINQUASIA RED, also known by its CAS number 2814-20-2, is a synthetic organic pigment. Chemically, it is identified as Pigment Red 170. Its primary function in pharmaceuticals is as a colorant for tablets, capsules, and powders. This coloring serves multiple purposes:

• Product Differentiation: Aids in distinguishing between different strengths or types of medication, reducing the risk of dispensing errors.
• Brand Recognition: Contributes to a consistent and recognizable product appearance for branded pharmaceuticals.
• Patient Compliance: Aesthetic qualities can sometimes improve patient acceptance and adherence to medication regimens.

Its use is governed by regulatory standards, such as those set by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which stipulate purity, toxicity, and approved usage levels for colorants in pharmaceuticals.

What are the Key Market Drivers for CINQUASIA RED?

The market for CINQUASIA RED is propelled by several interconnected factors within the broader pharmaceutical industry:

• Growth in Oral Solid Dosage Forms: The prevalence of tablets and capsules as primary drug delivery systems directly correlates with demand for colorants like CINQUASIA RED. Global production of these dosage forms is projected to continue expanding, driven by new drug approvals and generic market penetration.
• Increasing R&D Investment in Pharmaceuticals: Higher investment in drug discovery and development leads to more new chemical entities and formulations, many of which will incorporate colorants for differentiation and branding.
• Demand for Branded Pharmaceuticals: Pharmaceutical companies invest in branding to maintain market share and command premium pricing. Color is a fundamental component of this branding strategy.
• Regulatory Harmonization and Standards: As regulatory bodies worldwide establish and enforce stricter guidelines on excipient quality and safety, manufacturers favor well-characterized and compliant pigments, potentially benefiting established suppliers of CINQUASIA RED.
• Emerging Markets Pharmaceutical Growth: Rapid expansion of healthcare infrastructure and increasing access to medicines in emerging economies are increasing overall pharmaceutical production, thereby boosting excipient demand.

What are the Primary Challenges and Restraints in the CINQUASIA RED Market?

Despite growth drivers, the market for CINQUASIA RED faces significant challenges:

• Raw Material Price Volatility: The cost of petrochemical derivatives, which are the precursors for synthetic organic pigments like CINQUASIA RED, is subject to fluctuations in global oil prices and supply chain disruptions. This directly impacts manufacturing costs and profit margins.
• Competition from Alternative Colorants: The pharmaceutical industry has access to a wide array of approved colorants, including other synthetic pigments, natural colorants (e.g., iron oxides, anthocyanins), and inorganic pigments. Substitution by more cost-effective or preferred alternatives poses a competitive threat.
• Stringent Regulatory Scrutiny: Pharmaceutical excipients are subject to rigorous quality control and regulatory approval processes. Any perceived safety concerns or changes in regulatory status can lead to market exclusion. Compliance with Good Manufacturing Practices (GMP) is non-negotiable.
• Supply Chain Complexity and Reliability: Global pharmaceutical supply chains are intricate. Disruptions due to geopolitical events, natural disasters, or trade disputes can impact the availability and timely delivery of CINQUASIA RED.
• Environmental and Sustainability Concerns: Increasing pressure for environmentally friendly production processes and biodegradable materials may favor natural colorants over synthetic ones, although the performance characteristics of CINQUASIA RED in specific applications are a key differentiator.

Who are the Key Manufacturers and Suppliers of CINQUASIA RED?

The production of pharmaceutical-grade pigments is concentrated among a limited number of specialized chemical manufacturers. Key players in the pigment industry, some of whom supply pharmaceutical-grade versions of Pigment Red 170, include:

• DIC Corporation (Japan): A major global producer of pigments and fine chemicals, with a broad portfolio for various industries, including pharmaceuticals.
• BASF SE (Germany): Offers a wide range of chemical products, including pigments and excipients, catering to pharmaceutical applications.
• Clariant AG (Switzerland): A specialty chemicals company with a significant presence in pigments and color solutions, including pharmaceutical-grade offerings.
• Huntsman Corporation (USA): While known for a broader chemical portfolio, Huntsman has historically been involved in pigment production.
• Other regional manufacturers: Several smaller, specialized manufacturers in Asia and Europe also contribute to the supply chain, often focusing on specific grades or regional markets.

The market is characterized by a mix of large multinational corporations and niche suppliers. The ability to meet stringent pharmaceutical quality standards (e.g., USP, EP, JP monographs) and provide comprehensive regulatory documentation is critical for market access.

What is the Estimated Market Size and Growth Trajectory?

Quantifying the precise market size for CINQUASIA RED as a standalone excipient is challenging due to its classification within the broader pigment and pharmaceutical excipient markets. However, the global pharmaceutical excipient market was valued at approximately $10.2 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5.5% from 2023 to 2030, reaching an estimated $15.7 billion by 2030 [1].

CINQUASIA RED represents a niche segment within this larger market. Its growth trajectory is expected to mirror the overall growth of the oral solid dosage form market, tempered by competition. Conservative estimates suggest the specific market for pharmaceutical-grade red pigments, including CINQUASIA RED, could represent several hundred million dollars globally.

Projected Growth Factors:

• Increasing Demand for Branded Generics: The rise of branded generic drugs, particularly in emerging markets, will sustain demand for visually distinct formulations.
• Advancements in Drug Delivery: Innovations in tablet coating and capsule technology may enhance the application and stability of colorants.
• Geographic Expansion of Pharmaceutical Manufacturing: Growth in pharmaceutical production in regions like India, China, and Southeast Asia will drive regional excipient demand.

How do Regulatory Standards Impact CINQUASIA RED?

Regulatory standards are paramount for CINQUASIA RED's market viability. Compliance with pharmacopoeial monographs is a baseline requirement.

• United States Pharmacopeia (USP): CINQUASIA RED must meet the purity and assay requirements specified by USP if used in drugs marketed in the U.S.
• European Pharmacopoeia (EP): Similar requirements exist under the EP for drugs sold in Europe.
• Japanese Pharmacopoeia (JP): Compliance with JP standards is necessary for the Japanese market.

Manufacturers must also adhere to Good Manufacturing Practices (GMP) for excipients. This includes:

• Traceability: Full traceability of raw materials and production processes.
• Quality Control: Rigorous testing for impurities, heavy metals, and microbial contamination.
• Stability Studies: Data demonstrating the stability of the pigment under various storage conditions and in finished drug products.
• ICH Guidelines: Adherence to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, particularly those related to impurities and quality.

Changes in regulatory interpretations or the identification of new safety concerns related to specific pigments can lead to their delisting or restricted use, significantly impacting their market. For instance, concerns over certain azo dyes have led to increased scrutiny and a shift towards alternatives in some regions.

What is the Competitive Landscape for Red Pharmaceutical Pigments?

The competitive landscape for red pharmaceutical pigments is multifaceted:

• Direct Competition: Other synthetic red pigments like Pigment Red 57:1 (Lithol Rubine BK) or Pigment Red 48:2 (Lake Red C) are often considered for similar applications, depending on hue, opacity, and cost.
• Natural Colorants: Iron oxides (red, yellow, brown) are widely used, offering perceived "natural" appeal and good stability, though they may have limitations in achieving bright red hues. Annatto and carmine are also used but can be more expensive and have stability issues.
• Inorganic Pigments: Titanium dioxide (white) is often used in combination with other pigments to achieve desired shades and opacity.
• Color Lakes: Formed by precipitating soluble dyes (e.g., FD&C Red No. 40) onto an insoluble substratum, lakes offer improved stability and opacity compared to dyes, but regulatory approval pathways can differ.

Manufacturers of CINQUASIA RED compete on:

• Quality and Purity: Meeting stringent pharmacopoeial standards and demonstrating lot-to-lot consistency.
• Cost-Effectiveness: Balancing production costs with market pricing strategies.
• Regulatory Support: Providing comprehensive documentation and technical support to drug manufacturers for regulatory submissions.
• Supply Chain Reliability: Ensuring consistent and timely delivery.
• Technical Expertise: Offering formulation support and troubleshooting.

The trend towards "clean label" or naturally derived ingredients could pose a long-term challenge, but the performance characteristics, cost-effectiveness, and established regulatory acceptance of synthetic pigments like CINQUASIA RED ensure their continued relevance in many pharmaceutical applications.

What are the Financial Considerations for CINQUASIA RED Manufacturers?

Financial performance for CINQUASIA RED manufacturers is shaped by several key elements:

• Cost of Goods Sold (COGS):
  • Raw Materials: Volatility in petrochemical feedstock prices is a primary driver. Sourcing stable, high-purity precursors is critical.
  • Manufacturing Processes: Energy costs, labor, and capital investment in specialized synthesis and purification equipment influence COGS. Efficiency improvements through process optimization are vital.
  • Quality Control & Assurance: Extensive analytical testing and documentation required for pharmaceutical grade add significant costs.
• Pricing Strategy:
  • Pricing is influenced by the perceived value, competitive offerings, and the regulatory burden assumed by the supplier.
  • Long-term contracts with major pharmaceutical companies can provide revenue stability but may involve price concessions.
  • The premium for pharmaceutical-grade compliance (vs. industrial grade) is substantial.
• Research and Development (R&D):
  • While CINQUASIA RED is an established pigment, R&D may focus on improved synthesis routes for higher purity, reduced environmental impact, or enhanced dispersion properties for pharmaceutical formulations.
  • Development of custom color blends or improved particle size control can add value.
• Market Share and Volume:
  • Larger production volumes generally lead to economies of scale, reducing per-unit manufacturing costs.
  • Securing supply agreements with major pharmaceutical manufacturers is crucial for sustained sales volume.
• Intellectual Property:
  • While the basic synthesis of Pigment Red 170 is likely off-patent, specific purification methods, particle engineering, or novel applications might be patentable, offering a competitive advantage.
• Regulatory Compliance Costs:
  • Ongoing investment in maintaining GMP certifications, updating documentation, and responding to regulatory inquiries is a significant operational expense.

Key Financial Metrics to Monitor:

• Gross Profit Margins: Reflecting the company's ability to manage COGS relative to pricing.
• Operating Margins: Indicating efficiency in managing R&D, sales, and administrative expenses.
• Revenue Growth: Driven by volume increases and pricing adjustments.
• Return on Invested Capital (ROIC): Measuring the profitability of capital invested in manufacturing and R&D.

What is the Future Outlook for CINQUASIA RED?

The future outlook for CINQUASIA RED is cautiously optimistic, tied to the sustained growth of the pharmaceutical industry, particularly in oral solid dosage forms.

• Continued Demand from Established Applications: Its proven track record, regulatory acceptance, and ability to deliver specific red hues will ensure its continued use in a wide range of established pharmaceutical products.
• Growth in Emerging Markets: As pharmaceutical manufacturing expands in Asia, Latin America, and Africa, demand for reliable, high-quality excipients like CINQUASIA RED will likely increase.
• Technological Advancements: Innovations in pigment synthesis and particle characterization may lead to improved grades of CINQUASIA RED with enhanced performance characteristics, such as better dispersibility or higher stability in complex formulations.
• Increased Scrutiny on "Natural": While there is a general trend towards natural ingredients, the cost, performance, and regulatory hurdles associated with natural colorants mean that synthetic options will remain essential for many applications. Manufacturers will need to highlight the safety, consistency, and cost-effectiveness of CINQUASIA RED.
• Sustainability Innovations: Manufacturers that can demonstrate more sustainable production processes or develop recyclable packaging for their pigments may gain a competitive edge.

The market will remain competitive, with price pressure and the need for continuous regulatory compliance. Companies that can innovate in terms of product quality, sustainability, and supply chain resilience will be best positioned for long-term success.

Key Takeaways

• CINQUASIA RED is a synthetic organic pigment (Pigment Red 170) used in pharmaceutical oral solid dosage forms for product differentiation and branding.
• Market growth is driven by the expanding oral solid dosage market, pharmaceutical R&D, and demand for branded drugs, particularly in emerging economies.
• Key challenges include raw material price volatility, competition from alternative colorants (synthetic, natural, inorganic), and stringent regulatory requirements.
• The market is supplied by specialized chemical manufacturers with a focus on meeting pharmaceutical-grade quality and regulatory standards.
• The financial trajectory depends on managing COGS (especially raw material costs), effective pricing, operational efficiencies, and sustained sales volumes.
• The future outlook is positive, linked to pharmaceutical industry growth, but contingent on continued regulatory compliance, competitive pricing, and potential innovations in sustainable production or product performance.

Frequently Asked Questions

1. What are the specific regulatory limits for CINQUASIA RED in pharmaceutical products?

Specific regulatory limits are detailed within pharmacopoeial monographs (USP, EP, JP) and can vary based on the intended use, dosage form, and region. These limits typically address purity, heavy metal content, and maximum permissible usage levels to ensure patient safety.

2. How does the cost of CINQUASIA RED compare to natural red colorants?

Generally, synthetic pigments like CINQUASIA RED are more cost-effective than many natural red colorants, such as carmine or anthocyanins, especially when considering the scale of production and color intensity required for pharmaceutical applications. Iron oxides, another common red colorant, can be competitively priced depending on grade and purity.

3. What is the typical shelf life for pharmaceutical-grade CINQUASIA RED?

When stored under recommended conditions (typically cool, dry, and protected from light), pharmaceutical-grade CINQUASIA RED typically has a shelf life of several years, often exceeding 3-5 years, provided it remains in its original, sealed packaging.

4. Can CINQUASIA RED be used in pharmaceutical liquid or semi-solid formulations?

While primarily used in oral solid dosage forms, certain grades of pigments, including Pigment Red 170, can be formulated for use in pharmaceutical suspensions or topical semi-solid preparations. However, their application in liquid formulations requires careful consideration of dispersibility, stability, and potential interactions with other excipients.

5. What are the primary impurities to monitor in pharmaceutical-grade CINQUASIA RED?

Key impurities to monitor include residual starting materials, by-products from synthesis, heavy metals (e.g., lead, arsenic, mercury), and any microbial contamination. Strict quality control measures are in place to ensure these impurities remain below pharmacopoeial limits.

---

Citations

[1] Grand View Research. (2023). Pharmaceutical Excipients Market Size, Share & Trends Analysis Report By Type (Polymers, Liq uids, Sugars, Others), By Functionality (Fillers, Binders, Lubricants, Coatings, Others), By Application (Oral, Injectable, Topical, Others), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from [Grand View Research Website] (Note: Direct URL omitted per instructions; search for the report title on their site).